As one of nine National Institute of Allergy and Infectious Diseases (NIAID)-funded VTEU sites in the US, we conduct clinical trials of vaccines and therapeutics in adults and children. The VTEUs have played a key role in the National Institutes of Health's (NIH) effort to develop new and improved vaccines and therapies against infectious diseases for over 40 years.
Funded by NIAID to support translational research on human immunology, we perform in-depth studies to further our understanding of the protective immunological mechanisms that can be elicited in the GI microenvironment of humans. Moreover, because the normal GI flora (microbiota) is certain to influence the host immune response, we are conducting pioneering studies on the interactions between the local intestinal microbiota and the host immune response in humans.
In collaboration with investigators in the Malian Ministry of Health, we conduct epidemiologic and intervention studies with a focus on vaccine-preventable infectious diseases in children.
Malaria project field sites (Bandiagara Malaria Project in Mali, West Africa and Blantyre Malaria Project in Malawi, Central Africa)
These sites comprise multidisciplinary teams that study malaria molecular epidemiology, antimalarial drug resistance, malaria in pregnancy, and malaria-HIV interactions, and conduct candidate malaria vaccine trials.
We conduct pediatric vaccine trials in private practices and in the University of Maryland Pediatrics at the Harbor (PATH) clinic sponsored by NIH and industry.
GEMS is the largest, most comprehensive study of childhood diarrheal diseases ever conducted in developing country settings. This case-control study was conducted at seven diverse, high-burden sites in Asia and Africa: the Gambia, Kenya, Mali, Mozambique, Bangladesh, India and Pakistan. The study enrolled 22,568 children under 5 years of age, a sample size large enough to provide comprehensive data on the causes, incidence, and impact of the range of diarrheal diseases affecting children around the world.
Effectiveness and Safety of a New Formulation of the RotaTeqTM Vaccine
Non-interventional, prospective surveillance study on the effectiveness and safety of a new Vaccine Vial Monitor-Compatible (VVMC) formulation of RotaTeq™ for use in a developing-world setting. The project will also compare rates of confirmed intussusception among children vaccinated with the current formulation of RotaTeq™ to that of children vaccinated with the new formulation.
Surveillance of Rota-associated Diarrhea and Intussuception